Cory Renauer
Value, research analyst, biotech, small-cap

Cornerstone Therapeutics: Ignored And Clearly Undervalued

Cornerstone Therapeutics (NASDAQ:CRTX) is a specialty pharmaceutical company focused on products for hospitals and specialty markets. The company turned a profit early in its history, then went deep in the red acquiring products that fit its focus. In 2013, Cornerstone has come roaring back to profitability, and is one of the most exciting growth stories I've seen this year.

At the company's recent price of about $9.40, I see a near certain gain of at least 62% within a year, with a highly unlikely potential loss of 33%. I couldn't believe such a clearly undervalued company could be floating under our noses, until I realized just how many noses it was floating under. The Q2 2013 earnings call...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details